Anti-amyloid-Β single domain antibodies and their use in the treatment of alzheimer's disease

R3VQ single domain antibodies, enhanced by low-intensity pulsed ultrasound, address the BBB crossing challenge, effectively inhibiting amyloid-β aggregation and treating Alzheimer's disease by diffusing widely in the brain.

WO2026234055A1PCT designated stage Publication Date: 2026-11-12INST PASTEUR
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/063031
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing anti-amyloid-β antibodies face challenges in crossing the blood-brain barrier (BBB) effectively, leading to limited efficacy and safety issues in treating Alzheimer's disease, particularly due to high dosages and invasive delivery methods, and receptor-mediated transcytosis strategies are complex and costly.

Method used

Development of anti-amyloid-β single domain antibodies, such as R3VQ, which are smaller and can form dimers, allowing them to recognize both intra- and extracellular pools of amyloid-β, and are administered with low-intensity pulsed ultrasound to enhance BBB permeability, enabling widespread diffusion in the brain.

Benefits of technology

R3VQ antibodies effectively inhibit amyloid-β aggregation and treat associated diseases like Alzheimer's disease by efficiently crossing the BBB and diffusing throughout the brain, offering a safer and more effective therapeutic option.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000040_0001
    Figure IMGF000040_0001
  • Figure IMGF000019_0001_TABLE
    Figure IMGF000019_0001_TABLE
  • Figure IMGF000020_0001_TABLE
    Figure IMGF000020_0001_TABLE
Patent Text Reader

Abstract

The present disclosure relates to anti-Aβ single domain antibodies, multimers thereof and composition comprising thereof and their use in the treatment of a disease associated with the aggregation of Aβ selected from the group consisting of Alzheimer's disease, Down's syndrome and cerebral amyloid angiopathy.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Anti-amyloid-p single domain antibodies and their use in the treatment of Alzheimer's disease FIELD OF THE INVENTION

[0002] The present invention relates to anti-AfJ single domain antibodies, multimers thereof and composition comprising thereof and their use in the treatment of a disease associated with the aggregation of A(3 selected from the group consisting of Alzheimer’s disease, Down's syndrome and cerebral amyloid angiopathy.

[0003] BACKGROUND

[0004] The blood-brain barrier (BBB) separating the blood compartment from the central nervous system (CNS) has a main physiological function related to the homeostasis of the cerebral microenvironment. The key roles of the BBB, in the context of protecting a tissue with a low capacity for self-regeneration, are: 1) maintaining ionic and nutrient homeostasis, 2) regulating the levels of molecules acting as neurotransmitters or neuromodulators, 3) limiting the passage of plasma macromolecules which, if present in excess in brain tissue, could induce cell activation cascades with deleterious effects, 4) protection against toxins. The function of the BBB is therefore to regulate the inflow of these circulating substances according to the needs of the CNS, and to protect it against possible damage.

[0005] The organization of the BBB ensures its protection and homeostasis, with the counterpart of drastically limiting the penetration of potential CNS-targeted therapeutic molecules administered by the peripheral route (eg blood).

[0006] In particular, it is considered that immunoglobulins (large 150 kDa proteins) can cross the BBB at a very limited rate (<0.01% of the injected dose). To bypass the BBB and enhance the efficacy of passive immunotherapies for treating brain pathologies, the following strategies have been applied to leverage physical, biological, and nanotechnological mechanisms:

[0007] 1) Receptor-Mediated Transcytosis (RMT),

[0008] 2) Intranasal administration with CNS delivery via olfactory nerves,

[0009] 3) Temporary BBB permeabilization using focused ultrasound coupled to iv injections of dedicated antibodies,

[0010] 4) Nanotechnological vectors such as immunoliposomes,

[0011] 5) Viral vectors allowing in situ delivery of therapeutic antibodies,

[0012] 6) Direct intracranial delivery, for instance of biodegradable implants allowing sustained drug release into lesioned brain tissue.Regarding specifically the field of immunotherapies against Alzheimer's disease (AD), a majority are amyloid B-directed immunotherapies (anti-AB antibodies or antibodies against secretases - eg BACE1, involved in the amyloidogenic cleavage of APP, the precursor of AB) as a direct consequence of the still prevalent physiopathological “amyloid cascade model” in the research field.

[0013] Several preclinical research works made use of murine versions of anti-AB monoclonals tested in AD patients that either a) failed to reach clinical efficacy in subsequent phase Il-Ill trials (eg Bapineuzumab, Crenezumab) or are not approved by any medical authorities for AD treatment (Gantenerumab), b) have been initially FDA-approved despite limited or disputable symptoms improvement in treated patients and were finally abandoned in the recent years by the producing pharmaceutical company (eg Aducanumab, Adulhelm™), c) have been approved in the US, other countries and by EMA in spite of questionable benefice / risk balance (Lecanemab, Leqembi™). The most recent anti-AB monoclonals used in clinical trials (2 being FDA-approved: Lecanemab and Donanemab, Kisunla™) are administered peripherally at high dosages and succeed to lower amyloid loads.

[0014] To avoid high dosages administration or highly invasive stereotaxic injection, main strategies for BBB passages are nanotechnology-based approaches (eg immunoliposomes formulation) of which development remains challenging, viral vector with the risks associated to gene therapy and the most explored strategy in AD that is receptor-mediated transcytosis (RMT).

[0015] Thus, Trontinemab (a bivalent antibody complex coupling Gantenerumab, an anti-AB IgG, and an anti-TfR moiety for assuming “brain shuttle” RMT activity) shows rapid clearance of AB in AD patients with good safety profile (in comparison to standard immunotherapies)

[0016] While RMT is a promising strategy for delivering antibodies across the BBB, it may face significant limitations that impact efficacy and safety: endogenous competition and receptor downregulation, possible endothelial trapping and mitigation of delivery rate etc. In addition, the technology is hampered by bispecific antibody complexity: engineering antibodies with dual targeting (e.g., TfR + therapeutic mAb) requires each time a specific development and increases production costs.

[0017] SUMMARY OF THE INVENTION

[0018] As shown in the Examples 2 and 4, the inventors have found the R3VQ dimer (also named herein R3VQ-linker-R3VQ) binds both fibrillar and non-fibrillar AB and diffuse in brain parenchyma.

[0019] Therefore, in a first aspect of the invention, it is provided an isolated anti-AfJ multimeric single domain antibody comprising at least two anti-AfJ single domain antibodies linked together via a linker, wherein at least one or preferably each of the at least two anti-AfJ single domain antibodies comprise the following complementary determining regions (CDR):- CDR1 having the amino acid sequence selected from SEQ ID NO: 2 and variants thereof having up to 3, 2 or 1 amino acid additions, deletions, and / or substitutions compared to SEQ ID NO: 2;

[0020] - CDR2 having the amino acid sequence selected from SEQ ID NO: 3 and variants thereof having up to 3, 2 or 1 amino acid additions, deletions, and / or substitutions compared to SEQ ID NO: 3; and

[0021] - CDR3 having the amino acid sequence selected from SEQ ID NO: 4 and variants thereof having up to 3, 2 or 1 amino acid additions, deletions, and / or substitutions compared to SEQ ID NO: 4.

[0022] In various embodiments of the multimeric single domain antibody:

[0023] - the linker is a multimer of the amino acid sequence SEQ ID NO: 20 and / or

[0024] - one or preferably each of the at least two anti-Ap single domain antibodies comprise or consist of an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17, preferably the amino acid sequence SEQ ID NO: 15 or SEQ ID NO: 16, more preferably the amino acid SEQ ID NO: 15, or an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91 %, at least 92% at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17, preferably SEQ ID NO: 15 or SEQ ID NO: 16, more preferably SEQ ID NO: 15 and / or

[0025] - the anti-Ap multimeric single domain antibody is a homodimer or a heterodimer, preferably a homodimer - the anti-Ap multimeric single domain antibody comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27 and SEQ ID NO: 28, more preferably the amino acid SEQ ID NO: 25 or an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91 %, at least 92% at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to amino acid sequence selected from the group consisting of SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27 and SEQ ID NO: 28, more preferably the amino acid SEQ ID NO: 25.

[0026] As shown in the Examples, the inventors have found that the single domain antibodie R3VQ (VHH) that targets amyloid p as well as its homodimer R3VQ-linker-R3VQ recognize Ap intra- and extracellular pools (Example 1 ) and are able to inhibit the aggregation of amyloid p (Example 3).

[0027] Therefore, in a second aspect of the invention, it is provided an anti-Ap single domain antibody or anti-Ap multimeric single domain antibody comprising at least two anti-Ap single domain antibodies or a pharmaceutical composition comprisingthereof for use in a method for inhibitingthe aggregation of amyloid P,wherein the anti-Ap single domain antibody comprises the following complementary determining regions (CDR):

[0028] - CDR1 having the amino acid sequence selected from SEQ ID NO: 2 and variants thereof having up to 3, 2 or 1 amino acid additions, deletions, and / or substitutions compared to SEQ ID NO: 2;

[0029] - CDR2 having the amino acid sequence selected from SEQ ID NO: 3 and variants thereof having up to 3, 2 or 1 amino acid additions, deletions, and / or substitutions compared to SEQ ID NO: 3; and - CDR3 having the amino acid sequence selected from SEQ ID NO: 4 and variants thereof having up to 3, 2 or 1 amino acid additions, deletions, and / or substitutions compared to SEQ ID NO: 4.

[0030] The formation of aggregates of amyloid £ is associated with several pathologies such as Alzheimer’s disease, Down's syndrome and cerebral amyloid angiopathy.

[0031] Therefore, in a third aspect of the invention, it is provided an anti-Ap single domain antibody or an anti-Ap multimeric single domain antibody comprising at least two anti-Ap single domain antibodies or a pharmaceutical composition comprising thereof for use in a method for treatment of a disease associated with the aggregation of Ap, wherein the anti-Ap single domain antibody comprises the following complementary determining regions (CDR):

[0032] - CDR1 having the amino acid sequence selected from SEQ ID NO: 2 and variants thereof having up to 3, 2 or 1 amino acid additions, deletions, and / or substitutions compared to SEQ ID NO: 2;

[0033] - CDR2 having the amino acid sequence selected from SEQ ID NO: 3 and variants thereof having up to 3, 2 or 1 amino acid additions, deletions, and / or substitutions compared to SEQ ID NO: 3; and

[0034] - CDR3 having the amino acid sequence selected from SEQ ID NO: 4 and variants thereof having up to 3, 2 or 1 amino acid additions, deletions, and / or substitutions compared to SEQ ID NO: 4.

[0035] In an embodiment, the disease associated with the aggregation of Ap is selected from the group consisting of Alzheimer’s disease, Down's syndrome and cerebral amyloid angiopathy, preferably Alzheimer’s disease.

[0036] In various embodiments of the method for inhibiting the aggregation of amyloid £ or of the method for treatment of a disease associated with the aggregation of Ap:

[0037] - the anti-Ap single domain antibody or the anti-Ap multimeric single domain antibody is not linked, directly or indirectly, covalently or non-covalently to another molecule,

[0038] - the anti-Ap single domain antibody comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17, preferably the amino acid sequence SEQ ID NO: 15 or SEQ ID NO: 16, more preferably the amino acid SEQ ID NO: 15, or an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92% atleast 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17, preferably SEQ ID NO: 15, SEQ ID NO: 16, more preferably SEQ ID NO: 15, and / or

[0039] - the anti-Ap multimeric single domain antibody comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27 and SEQ ID NO: 28, more preferably the amino acid SEQ ID NO: 25 or an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91 %, at least 92% at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to amino acid sequence selected from the group consisting of SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27 and SEQ ID NO: 28, more preferably the amino acid SEQ ID NO: 25 and / or

[0040] - the anti-Ap single domain antibody or the anti-Ap multimeric single domain antibody is administered at a dose around 2.5 mg / kg or 5 mg / kg or 7.5 mg / kg or 10 mg / kg or 15mg / kg or 20 mg / kg or up to 25 mg / kg, preferably around 5 mg / kg or 7.5 mg / kg or 10 mg / kg, 15mg / kg, more preferably around 7.5 mg / kg and upto 10 mg / kg, up to 20 mg / kg or up to 50 mg / kg.

[0041] The method for inhibiting the aggregation of amyloid p is preferably an in vivo method for inhibiting the aggregation of amyloid p.

[0042] In Example 5, the inventors have shown, that the combination of the administration of R3VQ monomerwith the permeabilization of the BBB by ultrasound enables the VHH to cross the BBB and to diffuse throughout the brain parenchyma to a large extent compared to anti-AB VHH without permeabilization.

[0043] Therefore, the method for inhibitingthe aggregation of amyloid p or of the method for treatment of a disease associated with the aggregation of Ap may comprise an additional step of applying acoustic energy to a region of the brain of the subject.

[0044] The region of the brain is the entire brain, hemisphere, forebrain or a region of the brain of the subject known to be associated with Ap aggregates.

[0045] In various embodiments:

[0046] - the acoustic energy is ultrasound;

[0047] - the ultrasound is Low Intensity Pulsed Ultrasound (LIPU);

[0048] -the waves of the ultrasound is with an emission frequency between 100kHz and 20 MHz, between 100kHz and 10 MHz, preferably between 100kHz and 1 , 2 or 3 MHz;

[0049] - the acoustic pressure of the ultrasound is between 40 kPa and 3 MPa, preferably 0,4 or 0,5 MPa, and more preferably 0,2 MPA;- the duration of the application of acoustic energy is between 10 seconds and 10 minutes, preferably between 30 seconds and 5 min and more preferably between 1 and 2 minutes;

[0050] - the application is continuous or in a burst mode;

[0051] - a step of administering microbubbles, preferably intravenously is carried before, during and / or after the application of acoustic energy;

[0052] - the single domain antibody orthe multimeric single domain antibody is administered at a dose around 2.5 mg / kg or 5 mg / kg or 7.5 mg / kg or 10 mg / kg or 15mg / kg or 20 mg / kg or up to 25 mg / kg, preferably around 5 mg / kg or 7.5 mg / kg or 10 mg / kg or 15mg / kg, more preferably around 7.5 mg / kg and up to 10 mg / kg.

[0053] In another aspect of the invention, it is provided a method of delivering the anti-AfJ single domain antibody or the anti-Ap multimeric single domain antibody as defined above or a pharmaceutical composition comprisingthereof, that comprises a step of applying acoustic energy to a region of the brain of the subject as defined above.

[0054] BRIEF DESCRIPTION OF THE DRAWINGS

[0055] Figure 1: Drawing illustrating the low-intensity pulsed ultrasound (LIPU)

[0056] Figure 2: Immunohistology chemistry was performed to control R3VQ binding in APPxPS1-Ki brain tissue using immunofluorescence. R3VQ is able to label both extracellular deposits (white arrow heads) and intracellular deposits (black arrowhead) in CA1 layer of the hippocampus (dotted line area).

[0057] Figure 3: ELISA detection of coated synthetic pre-fibrillized A£1-42 peptide with increasing concentration of R3VQ monomer and RV3VQ dimer.

[0058] Figure 4: ELISA detection of A£1-42 peptide maintained soluble oligomeric form by HFIP treatment with increasing concentration of R3VQ monomer and RV3VQ dimer.

[0059] Figure 5: Kinetics of A£ aggregation (A£1 -42, 11 pM) by thioflavin T fluorescence of A(3 without (plain line) or with HFIP treatment (dotted line).

[0060] Figure 6: Kinetics of A(3 aggregation (A£1 -42, 11 pM) by thioflavin T fluorescence of A£ in presence of 2.75 pM of a non-specific VHH (control VHH, dotted line), R3VQ monomer (plain line, square) or RV3VQ dimer (plain line, triangle).

[0061] Figure 7: Histological analysis of frontal serial sections of APPxPS1-Ki mice injected with R3VQ monomer (A) or 4G8 mAb (B) in the dorsal hippocampus. Areas outlined in white delimit signal diffusion of injected antibodies on each brain sliceFigure 8: Quantitative analysis based on Cavalieri estimation of diffusion volumes of R3VQ monomer, R3VQ dimer and 4G8 mAb in frontal serial sections of APPxPSI -Ki mice injected with these VHH / antibodies in the dorsal hippocampus.

[0062] Figure 9: Histological analysis of frontal serial sections of APPxPSI -Ki mice iv injected at 15 mg / kg R3VQ monomer in the orbital sinus (A) with unilateral sonication using low-intensity pulsed ultrasound coupled to iv injected microbubbles or (B) without unilateral sonication and iv injection of microbubbles. White line perimeters delimit the area of diffusion.

[0063] Figure 10: Quantitative analysis based on Cavalieri estimation of diffusion volumes of R3VQ monomer and plasmatic IgG in frontal serial sections of APPxPSI -Ki mice injected with the VHH after unilateral sonication. Each lines correspond to the same mice

[0064] DETAILED DESCRIPTION

[0065] A. Anti-Ap single Domain Antibodies

[0066] As reported in the examples, isolated single domain antibodies (sdAbs) that bind to the amyloid-p 1 -42 (also called herein Ap 1-42 or Ap42) are provided.

[0067] The single domain antibodies (sdAb), also known as nanobodies®, are ten times smaller than conventional antibodies and they present numerous advantages: they are well produced, they are easily engineered, they can diffuse in tissues, they can bind to “non-conventional epitopes” or poorly accessible epitopes for conventional antibodies, they can penetrate into cells and bind intracellular antigens. To sum up, they combine the advantages of binding of antibodies with the advantages of small molecules.

[0068] The sdAb small size allows them to bind to epitopes that could be inaccessible to an IgG Fab arm.

[0069] The sdAb may be a variable region of camelid heavy-chain-only antibody (also called camelid single domain antibody, single domain VHH antibody or VHH) or a variable region of cartilaginous fish heavy-chain-only antibody (also called VNAR). In a preferred embodiment of the invention, the single domain antibody is a VHH.

[0070] Single domain antibodies comprise four framework regions (FR1 to FR4, respectively) and three complementary determining regions (CDR1 to CDR3, respectively).

[0071] The number and location of CDR region amino acid residues herein comply with the known CDR numbering criteria such as Kabat (Kabat, EA, etc. 1991 Sequences of Proteins of Immunological Interest, 5th Ed), IMGT (IMGT®:the international ImMunoGeneTics information system® http: / / www.imgt.org) or Chothia (ChothiaC., Lesk A.M. Canonical structures for the hypervariable regions of immunoglobulins. Mol. Biol.

[0072] 1987;196:901-917. doi: 10.1016 / 0022-2836(87)90412-8.), preferably IM GT.

[0073] The term "epitope" refers to a site on an antigen to which an immunoglobulin or antibody specifically binds (e.g., a specific site on A£42). Epitopes typically include at least 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14 or 15 consecutive or non-consecutive amino acids in a unique tertiary conformation. See, for example, Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, ed. G. E. Morris (1996).

[0074] A042 has the amino acid sequence: DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGWIA (SEQ ID NO. 1).

[0075] A£42 is, with Ap39, Ap40, A£41 , A£42 and Ap43, one of the several naturally occurring forms of amyloid £ protein (AP).

[0076] Ap monomers aggregate into various types of assemblies, including oligomers, protofibrils and amyloid fibrils. Amyloid fibrils are larger and insoluble, and they can further assemble into amyloid plaques, while amyloid oligomers are soluble and may spread throughout the brain (Guo-fang Chen at al., 2017).

[0077] Amyloid plaques with Ap as the main component are most commonly found in the neocortex in the brain of Alzheimer's disease patients (Haass C et al., 1992)

[0078] It is believed that Ap is the main cause of the Alzheimer’s disease (AD) and that the misfolding of the extracellular Ap protein accumulated in senile plaques with the intracellular deposition of misfolded tau protein in neurofibrillary tangles cause memory loss and confusion and result in personality and cognitive decline over time (Haass C. et al., 1993, Glenner GG. et al., 2012 et Selkoe DJ et al., 2016).

[0079] In the patent application WG2015071856, it was disclosed that the below VHHs R3VQ and R3VE bind to A£42 and recognize an epitope located in the central part of A£42 (see alsoTengfei Li et al., 2016).

[0080] Single domain antibody R3VO

[0081] The anti-Ap single domain antibody R3VQ is a VHH having the following amino acid sequence (CDRs are indicated in bold):

[0082] EVQLQASGGGLVQTGDSLRLSCADSGSTFRNYNIGWFRQTPGQAREFVAAVSRTGISTHVADSLQGRFTISR DNAKNTVYLQMNSLKPEDTAVYSCAAGRPGVGAVNRAMDYDYWGQGTQVTVSS (SEQ ID NO: 15).

[0083] Single domain antibody R3VE

[0084] The anti-Ap single domain antibody R3VE is a VHH having the following amino acid sequence (CDRs are indicated in bold):

[0085] EVQLEASGGGLVQTGDSLRLSCADSGSTFRNYNIGWFRQTPGQAREFVAAVSRTGISTHVADSLQGRFTISRD NAKNTVYLQMNSLKPEDTAVYSCAAGRPGVGAVNRAMDYDYWGQGTQVTVSS (SEQ ID NO: 16).In R3VE, the glutamine (Q) at position 5 of the amino acid sequence of R3VQ (SEQ ID NO: 15) has been replaced with a glutamic acid (E).

[0086] WO2015071856 also disclosed the use of R3VQ as delivery agent across the BBB of a diagnostic compound to which it is conjugated. In particular, it is shown that R3VQ-S-AF488, a conjugate comprising R3VQ covalently linked with the fluorescent diagnostic compound Alexa Fluor 488 (AF488), injected intravenously at high dose (50-mg / kg) in mice enables the visualization the extracellular amyloid plaques in brain.

[0087] As mentioned in the summary if the invention, now the inventors have found that R3VQ is able to inhibit A(3 aggregation in vitro and to bind intracellular forms of Afk Therefore, it is now shown that R3VQ is not only a delivery agent for diagnostic compound but a therapeutic agent by itself that targets not only extracellular forms of Ap but also intracellular forms.

[0088] The following table indicates the amino acid sequences of CDR1 to CDR3 of R3VQ and R3VE.

[0089] CDR Name SEQ ID NO Amino acid sequence

[0090] CDR1 R3VQ / R3VE 2 ADSGSTFRNYNIG

[0091] CDR2 R3VQ / R3VE 3 VSRTGISTHVADSLQG

[0092]

[0093] CDR3 R3VQ / R3VE 4 AAGRP GVGAVNRAMD YDY

[0094] Table 1: amino acid sequences of CDRs

[0095] Advantageously, it is provided herein an isolated anti-AfJ single domain antibody comprising the following complementary determining regions (CDR):

[0096] - CDR1 having the amino acid sequence selected from SEQ ID NO: 2 and variants thereof having up to 3, 2 or 1 amino acid additions, deletions, and / or substitutions compared to SEQ ID NO: 2;

[0097] - CDR2 having the amino acid sequence selected from SEQ ID NO: 3 and variants thereof having up to 3, 2 or 1 amino acid additions, deletions, and / or substitutions compared to SEQ ID NO: 3; and

[0098] - CDR3 having the amino acid sequence selected from SEQ ID NO: 4 and variants thereof having up to 3, 2 or 1 amino acid additions, deletions, and / or substitutions compared to SEQ ID NO: 4.

[0099] In an embodiment, the isolated anti-AfJ single domain antibody comprises the following complementary determining regions (CDR):

[0100] - CDR1 having the amino acid sequence SEQ ID NO: 2;

[0101] - CDR2 having the amino acid sequence SEQ ID NO: 3; and

[0102] - CDR3 having the amino acid sequence SEQ ID NO: 4.The anti-Ap single domain antibodies provided herein encompass variants having up to 6, 5, 4, 3, 2 or 1 amino acid additions, deletions, and / or substitutions in at least a framework region selected from FR1 , FR2, FR3 and FR4 compared to the FR1 , FR2, FR3 and FR4 of R3VQ or R3VE.

[0103] R3VQ R3VE R3VQ short R3VE short consensus FR1 EVQLQASGGGLVQT EVQLEASGGGLVQTGD VQLQASGGGLVQTGDS VQLEASGGGLVQTGDS XIX2X3VQLE / QASGGG GDSLRLSC (SEQ SLRLSC (SEQ ID LRLSC ( SEQ ID NO : LRLSC ( SEQ ID NO : LVQTGDSLRLSC ID NO : 5 ) NO : 9) 10 ) 12 ) with Xi is M or absent, X2 is A or absent , X3 is E, D, Q or absent (SEQ ID NO : 13 ) FR2 WFRQTPGQAREFVA WFRQTPGQAREFVAA WFRQTPGQAREFVAA WF RQT P GQARE F VAA WF RQ TP GQARE F VAA A (SEQ ID NO : (SEQ ID NO : 6) (SEQ ID NO : 6 ) (SEQ ID NO : 6 ) (SEQ ID NO : 6 ) 6)

[0104] FR3 RFTISRDNAKNTVY RF T I SRDNAKNT VYLQ RFT I SRDNAKNTVYLQ RFTISRDNAKNTVYLQ RF T I SRDNAKNTVYLQ LQMNSLKPEDTAVY MNSLKPEDTAVYS MNSLKPEDTAVYS MNSLKPEDTAVYS MNSLKPEDTAVYS

[0105] S (SEQ ID NO : (SEQ ID NO : 7 ) (SEQ ID NO : 7 ) (SEQ ID NO : 7 ) (SEQ ID NO : 7 ) 7 )

[0106] FR4 WGQGTQVTVSS (SE WGQGTQVTVSS ( SEQ WGQGTQVTV (SEQ WGQGTQVTV (SEQ WGQGTQVTVX4X5 Q ID NO : 8 ) ID NO : 8 ) ID NO : 11 ) ID NO : 11 ) with X4 is S or absent, X5 is S or absent (SEQ ID NO : 14 )

[0107]

[0108] Table 2: amino acid sequences of FRs

[0109] In a general way, the person skilled art will understand the modifications in the framework regions that do not affect the functionality of the single domain antibodies. Examples of such modification include modification at their N-terminal end with a sequence (EV, DV or QV) which corresponds to the first amino acids of the VHH domain of mature Camelidae antibodies after removal of the peptide signal sequence. In particular, the first amino acid residues (E) of both VHHs R3VQ and R3VE can be deleted without modifying the properties of these VHHs as well as the 2 last amino acid residues (SS).

[0110] “MA” residues or any other party of a cloning site may be added at the N terminus of the single domain antibody and / or a poly-histidine or any other tag at its C-terminus.

[0111] In an embodiment, the isolated anti-Ap single domain antibody comprises the following framework regions (FRs):

[0112] - FR1 having the amino acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 12, and SEQ ID NO: 13 and variants thereof having up to 5, 4, 3, 2 or 1 aminoacid additions, deletions, and / or substitutions compared to SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 12, or SEQ ID NO: 13;

[0113] - FR2 having the amino acid sequence SEQ ID NO: 6 and variants thereof having up to 5, 4, 3, 2 or 1 amino acid additions, deletions, and / or substitutions compared to SEQ ID NO: 6;

[0114] - FR3 having the amino acid sequence SEQ ID NO: 7 and variants thereof having up to 5, 4, 3, 2 or 1 amino acid additions, deletions, and / or substitutions compared to SEQ ID NO: 7,

[0115] - FR4 having the amino acid sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 11 and SEQ ID NO: 14 and variants thereof having up to 5, 4, 3, 2 or 1 amino acid additions, deletions, and / or substitutions compared to SEQ ID NO: 8, SEQ ID NO: 11 or SEQ ID NO: 14.

[0116] In an embodiment, the isolated anti-Ap single domain antibody comprises the following FRs:

[0117] - FR1 having the amino acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 12, and SEQ ID NO: 13;

[0118] - FR2 havingthe amino acid sequence SEQ ID NO: 6;

[0119] - FR3 havingthe amino acid sequence SEQ ID NO: 7,

[0120] - FR4 havingthe amino acid sequence SEQ ID NO: 8 or SEQ ID NO: 11.

[0121] In an embodiment, the isolated anti-Ap single domain antibody comprises the following FRs:

[0122] - FR1 havingthe amino acid sequence SEQ ID NO: 5;

[0123] - FR2 havingthe amino acid sequence SEQ ID NO: 6;

[0124] - FR3 havingthe amino acid sequence SEQ ID NO: 7;

[0125] - FR4 havingthe amino acid sequence SEQ ID NO: 8.

[0126] In an embodiment, the anti-Ap single domain antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17, preferably the amino acid sequence SEQ ID NO: 15 or SEQ ID NO: 16, more preferably the amino acid SEQ ID NO: 15, or an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17, preferably SEQ ID NO: 15, SEQ ID NO: 16, more preferably SEQ ID NO: 15.

[0127] As used herein, the term sequence "identity" has art-recognized meanings and the percentage of sequence identity between two nucleic acid or polypeptide molecules or regions can be calculated using published techniques. The percentage of sequence identity between two amino acid sequences is defined as the percentage of amino acid residues that are identical between these sequences.Methods of alignment of sequence for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted by the local homology algorithm of Smith et al. (1981 ), by the homology alignment algorithm of Needleman et al. (J. MoL Biol. 48:443 (1970), by the search for similarity method of Person et al. (Proc. Natl. Acad. Sci. USA, 85, 2444 (1988)), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wl), or by manual alignment and visual inspection. Computer implementations of these mathematical algorithms can be utilized for comparison of sequences to determine sequence identity. Such implementations include, but are not limited to: CLUSTAL in the PC / Gene program (available from Intelligenetics, Mountain View, California); the ALIGN program (Version 2.0) and GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Version 8 (available from Genetics Computer Group (GCG), 575 Science Drive, Madison, Wisconsin, USA). Alignments usingthese programs can be performed using the default parameters. The CLUSTAL program is well described by Higgins et al., Gene, 73:237 (1988); Higgins et al., CABIOS. 5:157 (1989); Corp et et al., Nucl. Acids Res.. 16:1088 (1988); Huang et al., CABIOS. 8:155 (1992); and Pearson et al., Methods MoL Biol.24:307 (1994). The ALIGN program is based on the algorithm of Myers and Miller, LABIOS.4: 11 (1988). The BLAST programs of Altschulet al. (J. MoL Biol., 215:403 (1990)) are based on the algorithm of Karlin and Altschul (PNAS USA. 90:5873 (1993)).

[0128] In an embodiment, the anti-AfJ single domain antibody consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17, preferably of the amino acid sequence SEQ ID NO: 15, SEQ ID NO: 16, more preferably of the amino acid sequence SEQ ID NO: 15, or of an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91 %, at least 92% at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17, preferably of the amino acid sequence SEQ ID NO: 15, SEQ ID NO: 16, more preferably of the amino acid sequence SEQ ID NO: 15.

[0129] It is also encompassed variants of R3VQ and R3VE. A variant of R3VQ or R3VE has at least one amino acid different than R3VQ or R3VE. In the expression such as "variant having 3, 2, or 1 amino acid difference(s)", the "amino acid difference" refers to the presence of amino acid change(s) or mutation(s) in the variant protein or polypeptide when compared to the original protein or polypeptide, including one or more amino acid insertion(s), deletion(s), or substitution(s) occurred on the original protein or polypeptide.

[0130] A variant of R3VQ or R3VE has at least one amino acid different than R3VQ or R3VE, respectively. A variant can contain at least 1, 2, 3, 4, 5, 6, 7, 8, 9 ,10, 11, 12, 13, 14, 15, 20, 25, 30, 40, or 50, etc., amino acidsdifferent than R3VQ or R3VE. A variant can contain an amino acid sequence that has at least 100, 105, 110, 115, 120, 121, 122, 123, 124, 125, 126, 127, 128, or 129 amino acids identical to the amino acid sequence of R3VQ or R3VE.

[0131] Advantageously, the variants have the same properties as the single domain antibody from which they derive. In particular, the variants selectively bind to A£, preferably to A£42 and / or A£40, in its oligomeric form and / or its fibrillar form, when intracellular and / or extracellular. The variants may also inhibit the aggregation of Afk

[0132] Methods of making variants of R3VQ or R3VE are known in the art. In some embodiments, the DNA sequence encoding R3VQ or R3VE is changed by one or more nucleotides encoding one or more amino acids of the VHH to generate a variant of R3VQ or R3VE. The variants can be generated in a recombinant vector comprising a DNA sequence encoding R3VQ or R3VE.

[0133] In a preferred embodiment, the single domain antibody is not linked, directly or indirectly, covalently or non-covalently to another molecule, for example a substance of interest. More specifically in this embodiment, the single domain antibody is not linked, directly or indirectly, covalently or non-covalently to substance of interest which is a diagnostic or therapeutic compound. Said substance of interest to which the single domain antibody is not linked may be a liposome or a polymeric entity comprising a diagnostic or therapeutic compound. Said therapeutic compound to which the single domain antibody is not linked may be selected from a peptide, an enzyme, a nucleic acid, a virus and a chemical entity. Said therapeutic compound to which the single domain antibody is not linked may be an analgesic compound, an anti-inflammatory compound, an antidepressant compound, an anticonvulsant compound, a cytotoxic compound or an anti-neurodegenerative compound. In a specific embodiment, the embodiment wherein the anti-AfJ single domain antibody is not linked, directly or indirectly, covalently or non-covalently to another molecule is with the proviso that said another molecule is not an anti-AfJ single domain antibody, preferably is with proviso that the anti-AfJ single domain antibody is not linked directly or indirectly with an anti-AfJ single domain antibody ,more preferably is with the proviso that the anti-AfJ single domain antibody is not a part of the multimer as disclosed in section B below.

[0134] In a preferred embodiment, the single domain antibody is not a part of a conjugate, in particular a part of a functional conjugate.

[0135] In an embodiment, the single domain antibody selectively binds to A£, preferably to A£42 and / or A|340, in its oligomeric form and / or its fibrillar form.In an embodiment, the single domain antibody selectively binds to intracellular Ap and / or extracellular Ap, preferably to intracellular and / or extracellular A£42 and / or Ap40.

[0136] In an embodiment, the single domain antibody selectively binds to intracellular Ap, preferably to A£42 and / or Ap40, in its oligomeric form and / or its fibrillar form.

[0137] The term "specifically bind to", "selectively bind to", "selectively binds to" or "specifically binds to" refers to the binding of an antibody to a predetermined epitope on an antigen. Typically, the antibody binds with an affinity (KD) of less than about 10-7M, for example, less than about 10-9M, 10-10M or 10-11M or even less. The term "KD" or "Kd" refers to the dissociation equilibrium constant for particular antibody-antigen interaction. Typically, the antibody of the present disclosure binds to A£42 and / or Ap40 with a dissociation equilibrium constant (KD) of less than about 10-7M, such as less than about 10-8M, 10-9M or 10-10M or even less, for example, as determined using surface plasmon resonance (SPR) techniques in a BIACORE instrument.

[0138] In an embodiment, the single domain antibody reduces the aggregation of amyloid £ by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% compared to a control. Advantageously, the control is a negative control. For example the control may be any antibody such as an immunoglobulin or a single domain antibody that does not bind to Ap. The evaluation of the reduction of aggregation may be carried out in vitro by a Thioflavin assay as disclosed in Example 3.

[0139] B. Multimeric single domain antibodies

[0140] Anti-Ap multimeric single domain antibodies are also provided. The anti-Ap multimeric single domain antibodies (multi-sdAb) comprise at least one anti-Ap single domain antibody as disclosed in section A linked to at least one other anti-Ap single domain antibody, the at least one other anti-Ap single domain antibody being preferably a single domain antibody also disclosed in section A.

[0141] Preferably, each anti-Ap single domain antibody present in the anti-Ap multimeric single domain antibody is the same. Preferably, the anti-Ap multimeric single domain antibody is a dimeric single domain antibody. The multimeric single domain antibody may be a homodimer or a heterodimer.

[0142] In a most preferred embodiment, the anti-Ap multimeric single domain antibody is an homodimer that is to say it comprises two copies of the same single domain antibody.

[0143] Advantageously, homodimers or heterodimers, preferably homodimers, of the single domain antibodies R3VQ or R3VE or variants thereof are provided.

[0144] In an embodiment, the anti-Ap multimeric single domain antibody comprises two anti-Ap single domain antibodies as disclosed in section A, most preferably two anti-Ap single domain antibodies comprising orconsisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17, preferably the amino acid sequence SEQ ID NO: 15 or SEQ ID NO: 16, more preferably the amino acid SEQ ID NO: 15, or an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91 %, at least 92% at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17, preferably SEQ ID NO: 15, SEQ ID NO: 16, more preferably SEQ ID NO: 15.

[0145] Advantageously, the anti-AfJ single domain antibodies of the multimer may be linked together via one or more type of linker. Thus, in an embodiment, the multimeric single domain antibody, preferably the dimer, comprises a linker.

[0146] The linker may be a peptide, peptide nucleic acid, or polyamide linkage. Suitable peptide linkers may include a plurality of amino acid residues, for example, 4, 5, 6, 7, 8, 9, 10, 15, 20 or 25 amino acids, such as (Gly)4(SEQ ID NO: 18), (Gly)5(SEQ ID NO: 19), (Gly)4Ser (SEQ ID NO: 20), (Gly)4(Ser)(Gly)4(SEQ ID NO: 21), or combinations thereof or a multimer thereof (for example a dimer, a trimer, or a tetramer, or greater of [(Gly)4(Ser)] such as [(Gly)4(Ser)]3(SEQ ID NO: 22), [(Gly)4(Ser)]4(SEQ ID NO: 23) or [(Gly)4(Ser)]5(SEQ ID NO: 25)).

[0147] Also included is a sequence, which has at least 50%, 60%, 70%, 80%, 90%, 95% or 99% identity thereto, using the default parameters of the BLAST computer program provided by HGMP.

[0148] Unless otherwise specified, dimers are abbreviated as follows:

[0149] R3VQ-linker-R3VQ means a dimer comprising two copies of R3VQ linked together via a linker,

[0150] R3VQ- R3VQ means a dimer comprising two copies of R3VQ linked together without any linker, R3VQ-(linker)-R3VQ means a dimer comprisingtwo copies of R3VQ linked together with or without a linker. One example of the homodimer R3VQ-linker-R3VQ has the following amino acid sequence (the linker is in bold):

[0151] EVQLQASGGGLVQTGDSLRLSCADSGSTFRNYNIGWFRQTPGQAREFVAAVSRTGISTHVADSLQGRFTI SRDNAKNTVYLQMNSLKPEDTAVYSCAAGRPGVGAVNRAMDYDYWGQGTQVTVSSGGGGSGGGGSGGGGS GGGGSEVQLQASGGGLVQTGDSLRLSCADSGSTFRNYNIGWFRQTPGQAREFVAAVSRTGISTHVADSLQ GRFTISRDNAKNTVYLQMNSLKPEDTAVYSCAAGRPGVGAVNRAMDYDYWGQGTQVTVSS (SEQ ID NO: 25).

[0152] It is the above R3VQ dimer that is used in the Examples.

[0153] One example of the homodimer R3VE-linker-R3VE has the following amino acid sequence (the linker is in bold):

[0154] EVQLEASGGGLVQTGDSLRLSCADSGSTFRNYNIGWFRQTPGQAREFVAAVSRTGISTHVADSLQGRFTI SRDNAKNTVYLQMNSLKPEDTAVYSCAAGRPGVGAVNRAMDYDYWGQGTQVTVSSGGGGSGGGGSGGGGSGGGGSEVQLEASGGGLVQTGDSLRLSCADSGSTFRNYNIGWFRQTPGQAREFVAAVSRTGISTHVADSLQ GRFTISRDNAKNTVYLQMNSLKPEDTAVYSCAAGRPGVGAVNRAMDYDYWGQGTQVTVSS (SEQ ID NO: 26).

[0155] One example of the heterodimer R3VQ-linker-R3VE has the following amino acid sequence (the linker is in bold):

[0156] EVQLQASGGGLVQTGDSLRLSCADSGSTFRNYNIGWFRQTPGQAREFVAAVSRTGISTHVADSLQGRFTI SRDNAKNTVYLQMNSLKPEDTAVYSCAAGRPGVGAVNRAMDYDYWGQGTQVTVSSGGGGSGGGGSGGGGS GGGGSEVQLEASGGGLVQTGDSLRLSCADSGSTFRNYNIGWFRQTPGQAREFVAAVSRTGISTHVADSLQ GRFTISRDNAKNTVYLQMNSLKPEDTAVYSCAAGRPGVGAVNRAMDYDYWGQGTQVTVSS (SEQ ID NO: 27).

[0157] One example of the heterodimer R3VE-linker-R3VQ has the following amino acid sequence (the linker is in bold):

[0158] EVQLEASGGGLVQTGDSLRLSCADSGSTFRNYNIGWFRQTPGQAREFVAAVSRTGISTHVADSLQGRFTI SRDNAKNTVYLQMNSLKPEDTAVYSCAAGRPGVGAVNRAMDYDYWGQGTQVTVSSGGGGSGGGGSGGGGS GGGGSEVQLQASGGGLVQTGDSLRLSCADSGSTFRNYNIGWFRQTPGQAREFVAAVSRTGISTHVADSLQ GRFTISRDNAKNTVYLQMNSLKPEDTAVYSCAAGRPGVGAVNRAMDYDYWGQGTQVTVSS (SEQ ID NO: 28).

[0159] In some embodiment, the multimeric single domain antibody comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identicalto an amino acid sequence selected from the group consisting of SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27 and SEQ ID NO: 28, more preferably comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27 and SEQ ID NO: 28, most preferably consists of the amino acid sequence selected from the group consisting of SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27 and SEQ ID NO: 28.

[0160] In some preferred embodiment, the multimeric single domain antibody comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence SEQ ID NO: 25, more preferably comprises the amino acid sequence SEQ ID NO: 25, most preferably consists of the amino acid sequence SEQ ID NO: 25.

[0161] In a preferred embodiment, the anti-AfJ multimeric single domain antibody is not linked, directly or indirectly, covalently or non-covalently to another molecule, for example a substance of interest. More specifically in this embodiment, the multimeric single domain antibody is not linked, directly or indirectly, covalently or non-covalently to a substance of interest which is a diagnostic or therapeutic compound. Said substance of interest to which the multimeric single domain antibody is not linked may be a liposome, a chemical compound, or a polymeric entity comprising a diagnostic or therapeutic compound. Said therapeutic compound to which the multimeric single domain antibody is not linked may be selected from a peptide, an enzyme, a nucleic acid, a virus and a chemical entity. Said therapeutic compound to which the multimericsingle domain antibody is not linked may be an analgesic compound, an anti-inflammatory compound, an antidepressant compound, an anticonvulsant compound, a cytotoxic compound or an anti-neurodegenerative compound.

[0162] In an embodiment, the multimeric single domain antibody selectively binds to Ap, preferablyto A£42 and / or Ap40, in its oligomeric form and / or its fibrillar form.

[0163] In an embodiment, the multimeric single domain antibody selectively binds to intracellular Ap and / or extracellular Ap, preferably to intracellular A£42 and / or A£40 and / or extracellular A£42 and / or A£40. In an embodiment, the multimeric single domain antibody selectively binds to intracellular Ap, preferably A£42and / or A£40 in its oligomeric form and / or its fibrillar form.

[0164] In an embodiment, the multimeric single domain antibody reduces the aggregation of amyloid £ by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% compared to a control. Advantageously, the control is a negative control. For example the control may be any antibody such as an immunoglobulin or a single domain antibody that does not bind to Ap. The evaluation of the reduction of aggregation may be carried out in vitro by a Thioflavin assay as disclosed in Example 3.

[0165] D. Nucleic Acids and Cells

[0166] In another aspect an isolated nucleic acid sequence that encodes the anti-Ap single domain antibody as disclosed in section A, or the multimeric single domain antibody as disclosed in section B is provided. The anti-Ap single domain antibody may be any anti-Ap single domain antibody described in Section A above. The multimeric single domain antibody may be any multimeric single domain antibody described in Section B above.

[0167] Also provided are recombinant vectors comprising the isolated nucleic acid sequence. The recombinant vector can be a vector for eukaryotic or prokaryotic expression, such as a plasmid, a phage for bacterium introduction, a YAC able to transform yeast, a viral vector and especially a retroviral vector, or any expression vector. An expression vector as defined herein is chosen to enable the production of single domain antibody or multimeric single domain antibody, either in vitro or in vivo.

[0168] In one embodiment, the expression vector is pHEN6, pET23, pET22, pASK-IBA2 or pCI. In one embodiment, the expression vector encodes a protease cleavage site, such as TEV cleave site, inserted between the single domain antibody / multimeric single domain antibody protein coding sequence and a protein purification Tag, such as polyHis tag or strep tag. In a preferred embodiment, the expression vector encodes a His tag or a strep tag. In one embodiment, a TEV cleavage site is positioned to remove the His tag, for example, after purification.The expression vector can comprise transcription regulation regions (including promoter, enhancer, ribosome binding site (RBS), polyA signal), a termination signal, a prokaryotic or eukaryotic origin of replication and / or a selection gene. The features of the promoter can be easily determined by the man skilled in the art in view of the expression needed, i.e ., constitutive, transitory or inducible (e.g. IPTG), strong or weak. The vector can also comprise sequences enabling conditional expression, such as sequences of the Cre / Lox system or analogue systems.

[0169] In various embodiments, the expression vector is a plasmid, a phage for bacterium introduction, a YAC able to transform yeast, a viral vector, or any expression vector. An expression vector as defined herein is chosen to enable the production of a single domain antibody or multimeric single domain antibody, either in vitro or in vivo.

[0170] The nucleic acid molecules according to the invention can be obtained by conventional methods, known per se, following standard protocols such as those described in Current Protocols in Molecular Biology (Frederick M. AUSUBEL, 2000, Wiley and son Inc., Library of Congress, USA). For example, they may be obtained by amplification of a nucleic sequence by PCR or RT-PCR or alternatively by total or partial chemical synthesis.

[0171] The vectors are constructed and introduced into host cells by conventional recombinant DNA and genetic engineering methods, which are known per se. Numerous vectors into which a nucleic acid molecule encoding the anti-AfJ single domain antibody or the multimeric single domain antibody of the invention may be inserted in order to introduce it and to maintain it in a host cell are known per se; the choice of an appropriate vector depends on the use envisaged for this vector (for example replication of the sequence of interest, expression of this sequence, maintenance of the sequence in extrachromosomal form or alternatively integration into the chromosomal material of the host), and on the nature of the host cell. In another aspect a recombinant cell comprising the isolated nucleic acid sequence of the invention is provided. In some embodiments the cell is a eukaryotic cell.

[0172] In another aspect methods of producing the single domain antibody or the multimeric single domain antibody are provided. The methods comprise culturing the recombinant cell comprising the isolated nucleic acid sequence that encodes the single domain antibody or the multimeric single domain antibody under conditions sufficient for production of the single domain antibody or the multimeric single domain antibody.

[0173] E. Pharmaceutical Compositions, Uses, and Methods

[0174] Also provided are pharmaceutical compositions comprising the anti-Ap single domain antibody as disclosed in section A, or the multimeric single domain antibody as disclosed in section B.Such compositions may comprise any suitable and pharmaceutically acceptable carrier, diluent, adjuvant or buffer solution.

[0175] The pharmaceutical compositions may be administered in any effective, convenient manner effective for treating a patient’s disease including, for instance, administration by intravenous route among others. In therapy or as a prophylactic, the active agent may be administered to a subject as an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic.

[0176] For administration to mammals, and particularly humans, it is expected that the dosage of the active agent will be around 2.5 mg / kg, 5 mg / kg, 7.5 mg / kg, 10 mg / kg, 15mg / kg, 20 mg / kg or up to 25 mg / kg, preferably around 5 mg / kg, 7.5 mg / kg, 10 mg / kg, 15mg / kg more preferably around 7.5 mg / kg and up to 10 mg / kg, up to 20 mg / kg or up to 50 mg / kg. The physician in any event will determine the actual dosage, which will be most suitable for a subject which will be dependent on factors including the age, weight, sex and response of the subject. The above dosages are exemplary of the average case. There can, of course, be instances where higher or lower dosages are merited, and such are within the scope of this invention.

[0177] The pharmaceutical compositions may be for use to treat or ameliorate the condition of a patient in need thereof.

[0178] In some embodiments of the methods, the pharmaceutical composition is administered to a subject having a pathology selected from the group consisting of Alzheimer’s disease, Down's syndrome and cerebral amyloid angiopathy.

[0179] F. Methods of inhibiting aggregation of amyloid 0

[0180] The inventors have shown in Example 3, that R3VQ and homodimer of R3VQ both inhibit the aggregation of A042.

[0181] Therefore, invention encompasses methods for inhibiting the aggregation of amyloid p, preferably A£42, comprising a step of administering the single domain antibody as disclosed in section A, or the multimeric single domain antibody as disclosed in section B to a subject in need thereof.

[0182] The method for inhibiting the aggregation of amyloid £ is preferably an in vivo method for inhibiting the aggregation of amyloid p.

[0183] Preferably, the single domain antibody as disclosed in section A, or the multimeric single domain antibody as disclosed in section B reduces the aggregation of amyloid £ by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% compared to a control. Advantageously, the control is a negative control. For example the control maybe any antibody such as an immunoglobulin ora single domain antibody that doesnot bind to Ap. The evaluation of the reduction of aggregation may be carried out in vitro by a Thioflavin assay as disclosed in Example 3.

[0184] In some embodiments, the anti-Ap single domain antibody is selected from R3VQ or R3VE or multimer thereof such as R3VQ-(linker)-R3VQ, R3VE-(linker)-R3VE, R3VQ-(linker)-R3VE orR3VE-(linker)-R3VQ. In some preferred embodiments, the anti-Ap single domain antibody is R3VQ or R3VQ-R3VQ or R3VQ-linker-R3VQ.

[0185] G. Methods of treatment

[0186] Also provided is the anti-Ap single domain antibody as disclosed in section A, or the multimeric anti-Ap single domain antibody as disclosed in section B or a pharmaceutical composition comprising thereof for use as a medicament.

[0187] The present invention also relates to the use of the anti-Ap single domain antibody as disclosed in section A, or the multimeric anti-Ap single domain antibody as disclosed in section B or a pharmaceutical composition comprising thereof in the manufacture of a medicament.

[0188] The present invention also relates to the anti-Ap single domain antibody as disclosed in section A, or the multimeric anti-Ap single domain antibody as disclosed in section B or a pharmaceutical composition comprising thereof for use in a method for treatment of a disease associated with the aggregation of Ap. The term "treating" or "treatment" as used herein and as is well understood in the art, means an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilized (i.e. not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, diminishment of the reoccurrence of disease, and remission (whether partial or total), whether detectable or undetectable. "Treating" and "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. "Treating" and "treatment" as used herein also include prophylactic treatment. For example, a subject with early stage AD can be treated to prevent progression with a single domain antibody, a multimeric single domain antibody ora pharmaceutical composition described herein to prevent progression.

[0189] The terms “subject” and “patient”, are used interchangeably herein and refer to any animals for whom treatment is desired, particularly humans. Animals includes humans, domestic and farm animals, and zoo, sports, or pet animals. Preferably, the patients are mammals, most preferably humans.

[0190] The present invention also relates to a method for treatment of a disease associated with the aggregation of Ap, in a subject in need thereof, comprising administering to the subject, the anti-Ap single domainantibody as disclosed in section A, or the multimeric anti-AfJ single domain antibody as disclosed in section B ora pharmaceutical composition comprising thereof.

[0191] The present invention also relates to the use of the anti-AfJ single domain antibody as disclosed in section A, or the multimeric anti-AfJ single domain antibody as disclosed in section B or a pharmaceutical composition comprisingthereof inthe manufacture of a medicament for treatment of a disease associated with the aggregation of Afk

[0192] In an embodiment, the disease is caused by the extracellular aggregation of A£ and / or the intracellular aggregation of Afk

[0193] In an embodiment, the disease is associated with the aggregation of A£ in central nervous system, preferably in brain.

[0194] Disease associated with the aggregation of A£ may be selected from the group consisting of Alzheimer’s disease, Down's syndrome and cerebral amyloid angiopathy, preferably Alzheimer’s disease.

[0195] Therefore, the present invention also relates to the anti-AfJ single domain antibody as disclosed in section A, or the multimeric anti-AfJ single domain antibody as disclosed in section B or a pharmaceutical composition comprising thereof for use in a method for treatment of a disease selected from the group consisting of Alzheimer’s disease, Down's syndrome and cerebral amyloid angiopathy, preferably Alzheimer’s disease.

[0196] The present invention also relates to a method for treatment of a disease selected from the group consisting of Alzheimer’s disease, Down's syndrome and cerebral amyloid angiopathy, preferably Alzheimer’s disease, in a subject in need thereof, comprising administering to the subject, the anti-AfJ single domain antibody as disclosed in section A, or the multimeric anti-AfJ single domain antibody as disclosed in section B ora pharmaceutical composition comprising thereof.

[0197] The present invention also relates to the use of the anti-AfJ single domain antibody as disclosed in section A, or the multimeric anti-AfJ single domain antibody as disclosed in section B or a pharmaceutical composition comprising thereof in the manufacture of a medicament for treatment of a disease selected from the group consisting of Alzheimer’s disease, Down's syndrome and cerebral amyloid angiopathy, preferably Alzheimer’s disease.

[0198] In some embodiments, the anti-AfJ single domain antibody is selected from R3VQ or R3VE, preferably not linked, directly or indirectly, covalently or non-covalently to another molecule, or a dimer of R3VQ and / or R3VE such as R3VQ-(linker)-R3VQ, R3VE-(linker)-R3VE, R3VQ-(linker)-R3VE or R3VE-(linker)-R3VQ.In some preferred embodiments, the anti-AfJ single domain antibody is R3VQ, preferably not linked, directly or indirectly, covalently or non-covalently to another molecule, or a homodimer of R3VQ, preferably the homodimer of R3VQ having the amino acid sequence SEQ ID NO: 25.

[0199] In an embodiment, the method for treatment of the invention comprises a step of permeabilization of the brain blood barrier (BBB).

[0200] Indeed, whereas as mentioned in the summary, it is considered that antibodies can cross the BBB at a very limited rate (<0.01% of the injected dose), the inventors have shown, in Example 5, that the combination of the administration of an anti-AB VHH with the permeabilization of the BBB by ultrasound enables the anti-AB VHH to cross the BBB and to diffuse throughout the brain parenchyma to a large extent compared to anti-AB VHHs without permeabilization.

[0201] Advantageously, the step of permeabilization of the BBB may be carried out by acoustic energy such as ultrasound (eg developed by different companies Carthera, Insightec, TheraSonic).

[0202] In an embodiment, the ultrasound is Low Intensity Pulsed Ultrasound (LIPU),

[0203] Thus, in an embodiment, the method for treatment of the invention comprises a step of applying acoustic energy to a region of the brain of the subject.

[0204] The region of the brain may be the entire brain, hemisphere, forebrain or a region of the brain of the subject known to be associated with A£ aggregates.

[0205] In a preferred embodiment, the acoustic energy is ultrasound.

[0206] In an embodiment, the waves of the ultrasound are with an emission frequency between 100kHz and 20 MHz, between 100kHz to 10 MHz, preferably between 100kHz to 1, 2 or 3 MHz. At these frequencies, the ultrasounds are administered at a clinically safe level.

[0207] In an embodiment, the acoustic pressure of the ultrasound is between 40 kPa and 3 MPa, preferably 0,4 or 0,5 MPa, and more preferably 0,2 MPA.

[0208] In an embodiment, the duration of the application of acoustic energy is between 10 seconds and 10 minutes, preferably between 30 seconds and 5 min and more preferably between 1 and 2 minutes.

[0209] In an embodiment, the application is continuous. In another embodiment, the application is in a burst mode. In an embodiment, the acoustic energy is applied directly on the skull. In another embodiment, the acoustic energy is applied with an acoustic energy apparatus implanted in the skull of the subject (WO2011 / 101492, US2017 / 0259086).

[0210] In a preferred embodiment, the method for treatment of the invention comprises also a step of administering microbubbles (i.e. micron-sized bubbles).Indeed, a solution of microbubbles injected into the patient may improve the effectiveness of the ultrasound treatment. Ultrasonic oscillations of microbubbles result in modulation of the blood-brain barrier permeability.

[0211] The microbubbles are typically microbubbles of gas. The gas may be for example sulfur hexafluoride (SFs), octafluoropropane (C3F8) or octafluoropropane (C4F10) - They may be stabilized by phospholipids.

[0212] The microbubbles may have a mean diameter in a range from 1 pm to 10 pm. In some embodiments, the microbubbles have a mean diameter in a range from 4 pm to 5 pm. In some other embodiments, the microbubbles have a mean diameter in a range from 2 to 6 pm. In some embodiments, the microbubbles have a mean diameter of approximately 7 pm, 6 pm, 5 pm, 4 pm, 3 pm or 2 pm. In a particular embodiment, the microbubbles have a mean diameter of approximately 2.5 pm.

[0213] The administration of microbubbles may be before, after or during the application of ultrasound, preferably before. In an embodiment, the microbubbles are administered intravenously.

[0214] In a general way, for administration to mammals, and particularly humans, it is expected that, in order to deliver the active agent (herein anti-AfJ single domain antibody as disclosed in section A, or the multimeric anti-Ap single domain antibody as disclosed in section B) to the brain, the dosage of the active agent will be around 10 mg / kg, 20 mg / kg or up to 50 mg / kg.

[0215] However, as shown by the inventors in Example 5, the combination of the active agent with ultrasound enables its diffusion throughout the brain parenchyma at lower doses.

[0216] Therefore, in the embodiment where ultrasounds are administered, for administration to mammals, and particularly humans, it is expected that the effective dosage of the active agent will be 2 to 5 times lower than the one without the application of ultrasound. It may be for example around 2.5 mg / kg, 5 mg / kg, 7.5 mg / kg, 10 mg / kg, 15mg / kg, 20 mg / kg or up to 25 mg / kg, preferably around 5 mg / kg, 7.5 mg / kg, 10 mg / kg, 15mg / kgmore preferably around 7.5 mg / kg and upto 10 mg / kg.

[0217] It was previously disclosed methods of delivery therapeutical agent such as high molecular weight antibodies to a brain by applying acoustic energy (WO2021 / 108861, US2024 / 0230680) but with no conclusive results on amelioration of clinical symptoms. The inventors have shown, for the first time, that the application of ultrasound according to the features disclosed above enables single domain antibodies to cross the BBB and reach their intracerebral target at suitable therapeutic dose even when administered at low dose (e.g. lower than 10 mg / kg, preferably lower than 7.5mg / kg).

[0218] Therefore, it is also provided herein a single domain antibody or a multimer thereof, in particular a dimer thereof, ora pharmaceutical composition comprisingthereof for use in a methodfortreatment of a disease associated with the aggregation of A£, wherein the method for treatment of the invention comprises a stepof applying acoustic energy to a region of the brain of the subject. The various embodiments of the step of applying acoustic energy to a region of the brain of the subject and / or of the step of administering the single domain antibody or the multimer thereof, in particular the dimer thereof, and / or of the optional step of administering microbubbles may be the same as disclosed above.

[0219] H. Methods of delivering

[0220] It is also provided a method of deliveringthe anti-Ap single domain antibody as disclosed in section A, orthe multimeric anti-Ap single domain antibody as disclosed in section B or a pharmaceutical composition comprising thereof.

[0221] Advantageously, the anti-Ap single domain antibody as disclosed in section A, or the multimeric anti-Ap single domain antibody as disclosed in section B ora pharmaceutical composition comprising thereof is to be delivered to the brain or a region thereof.

[0222] The present invention also relates to a method of deliveringthe anti-Ap single domain antibody as disclosed in section A, or the multimeric anti-Ap single domain antibody as disclosed in section B in a subject comprising: administeringto the subject the anti-Ap single domain antibody as disclosed in section A, orthe multimeric anti-Ap single domain antibody as disclosed in section B, and applying acoustic energy to a region of the brain of the subject.

[0223] In a preferred embodiment, the acoustic energy is ultrasound.

[0224] In an embodiment, the waves of the ultrasound are with an emission frequency between 100kHz and 20 MHz, between 100kHz to 10 MHz, preferably between 100kHz to 1, 2 or 3 MHz, more preferably 1MHz. At these frequencies, the ultrasounds are administered at a clinically safe level.

[0225] In an embodiment, the acoustic pressure of the ultrasound is between 40 kPa and 3 MPa, preferably 0,4 or 0,5 MPa, and more preferably 0,2 MPA.

[0226] In an embodiment, the duration of the application of acoustic energy is between 10 seconds and 10 minutes, preferably between 30 seconds and 5 min and more preferably between 1 and 2 minutes.

[0227] In a preferred embodiment, the method of delivering comprises also a step of administering microbubbles, preferably intravenously.

[0228] The administration of microbubbles may be before, after or during the administration of ultrasound, preferably before. In an embodiment, the microbubbles are administered intravenously.

[0229] In a preferred embodiment, the anti-Ap single domain antibody as disclosed in section A, orthe multimeric anti-Ap single domain antibody as disclosed in section B is administered intravenously. In an embodiment, the anti-Ap single domain antibody as disclosed in section A, or the multimeric anti-Ap single domain antibody as disclosed in section B is administered at a dosage around 2.5 mg / kg, 5 mg / kg, 7.5 mg / kg, 10mg / kg, 15mg / kg, 20 mg / kg or up to 25 mg / kg, preferably around 5 mg / kg, 7.5 mg / kg, 10 mg / kg, 15mg / kg more preferably around 7.5 mg / kg and up to 10 mg / kg.

[0230] It is also provided herein a method of delivering a single domain antibody, a multimer thereof, in particular a dimer thereof, a pharmaceutical composition comprising thereof comprising a step of applying acoustic energy to a region of the brain of the subject. Advantageously, the single domain antibody, the dimer thereof or a pharmaceutical composition is to be delivered to the brain or a region thereof. The various embodiments of the step of applying acoustic energy to a region of the brain of the subject or of the step of administering the single domain antibody or the multimer thereof, in particular the dimerthereof or of the optional step of administering microbubbles may be the same as disclosed above.

[0231] EXAMPLES

[0232] Material and methods

[0233] Antibody production

[0234] Following immunization of an alpaca with synthetic fibrillar A£1 -42 peptide (Bachem), a VHH named R3VQ was selected through phage display. The gene encoding for the dimeric form has been designed according to the needs (addition of the linker between the 2 VHHs, optimizing the nucleotide sequences for the expression) and has been synthesized by Eurofins.

[0235] Both monomeric and dimeric forms of R3VQ, named respectively in the examples R3VQ monomer and R3VQ dimer, were modified with an additional cystein for site-specific conjugation and an N-terminal His tagfor purification. The VHH variants were expressed in E. coli BL21 (DE3) from pET23d vectors and purified by immobilized metal affinity chromatography (IMAC), followed by size exclusion chromatography on an AKTA Pure system using a HiLoad Superdex 16 / 600200 pg column (Cytiva).

[0236] The identity and purity of the VHHs were confirmed by amino acid analysis, SDS-PAGE, and mass spectrometry.

[0237] For in vivo use, an additional washing step was added during IMAC using PBS 1X triton X1140.1 % buffer to wash out LPS from bacteria and final productwas filtered with a 0.22 pm filter.

[0238] The addition of an extra cysteine allows specific C-terminal conjugation to biotin or to AF488.

[0239] The two constructs (R3VQ monomer and R3VQ dimer) were validated for amyloid binding by immunofluorescence on APPxPSI -KI mouse brain sections and in ELISA assay.

[0240] ELISA

[0241] Api -42 (Abeam) solutions were prepared at a final concentration of 220 nM (1 pg / mL) in 1 X PBS buffer. Two AB conformations were tested: standard synthetic A£1-42 or HFIP-pretreated A£1-42(Hexafluoroisopropanol, a polar solvent that prevents aggregation). Samples were incubated at 37 °C for 15 minutes under agitation (60 RPM) to partially induce fibrillization. Then, 100 pL of each solution (aggregated or not) were added to the wells of a 96-well ELISA plate (Thermo Scientific Nunc MaxiSorp) for antigen adsorption. The plate was incubated overnight at 37 °C. Plates were then washed three times with PBS Tween-200.1% (PBST) to remove non-specific binding.

[0242] A solution was prepared for R3VQ monomer and R3VQ dimer labelled with AF 488 in PGT buffer (PBS 1X, 0.5% gelatin, 0.1% Tween-20) at an initial concentration of 10 pg / mL (-770 nM). A series of six successive 1 :3 dilutions was made from the initial solution. For each variant, 100 pL of the initial solution and of each dilution were added to wells previously coated with the antigen. The last row of the ELISA plate was used as a negative control and incubated with PGT buffer alone, without antibody. Incubation was carried out at 37 °C for 1 hour, followed by three washes with PBST.

[0243] The Fluorescence was read using an Infinite® 200 microplate reader (Tecan).

[0244] Thioflavin T assay

[0245] Synthetic A£1-42 and HFIP-treated A£ 1-42 peptides (Abeam) were used. Peptides were reconstituted at 220 pM in suspension buffer (1 % NH4OH, PBS / NaCl 300 mM), aliquoted, flash-frozen in liquid nitrogen, and stored at -80°C until use.

[0246] Kinetics of A£ fibril formation were assessed by thioflavin T (ThT) fluorescence using a Jasco FP-8200 spectrofluorimeter. A working solution of 500 pLAfJat 11 pM was prepared in PBS / NaCl 300 mM, followed by the addition of 1 pL of ThT (final concentration: 1 pM). ThT intercalates into amyloid fibrils and emits a fluorescent signal, which is proportional to the amount of fibrils formed. By monitoring the increase in fluorescence, the kinetics of Ap aggregation can be determined.

[0247] It was measured the aggregation kinetics of Api-42 alone and in the presence of 0.25 molar equivalents (2.75 pM) of biotinylated R3VQ monomer, or R3VQ dimer, or control VHH targeting SARS-CoV-2 and that should not interfere with AB aggregation. Aggregation of HFIP-treated Api-42 was also analyzed alone. All VHHs were prepared in PBS / NaCl 300 mM. For co-incubation experiments, 10 pL of VHH solution was added to the 11 pM Ap solution to reach a final concentration of 2.75 pM VHH.

[0248] Samples were incubated at 37°C under agitation (60 RPM) in the spectrofluorimeter. Fluorescence readings were taken every 30 seconds for 8000 seconds using 450 nm excitation and 490 nm emission wavelengths.

[0249] Animal model

[0250] The APPxPS1-Ki mouse model was used. APPxPS1-Ki mice harbor the M233T & L235P knocked-in mutations of the endogenous mouse PS1 gene and overexpresses Swedish K670N / M671L and London V717I APP mutations under the control of a Ty1 promoter (WC2005032244 et Casas et al., 2004). TheAPPxPS1-Ki line develops an early-onset and aggressive neuropathological phenotype, including the formation of intracellular inclusions, extracellular amyloid deposits and AB oligomer accumulation. APPxPSI -Ki male mice between 4 and 6 months-old were used for the present study. PS1 -Ki aged-matched littermates were used as controls as these mice displayed no brain lesions and no altered behavioral / cognitive phenotypes. The general health of mice was regularly checked, and body weights were assessed weekly throughout the experimental period. All experiments on animals were conducted in accordance with the ethical standards of French and European laws (2010 / 63 / UE). The supervisor of the study has received official approval from the French Ministry of Agriculture to carry out research and experiments on animals (Authorization No. A-75-1741). The project was approved by the local ethics Committee (Charles Darwin Committee) and the French “Ministere de I’Enseignement Superieur, de la Recherche et de I’lnnovation” (APAFIS #48516-2024032518409824 v4 ).

[0251] Intracranial injections of antibodies

[0252] Stereotaxic injections of VHH / immunoglobulin were performed in anesthetized mice using 4% isoflurane in 4 L min-1 oxygen for anesthesia induction and 1.2-1.8% isoflurane in 1 L min-1 oxygen for anesthesia maintenance.

[0253] At the rate of 0.2 pL / min, a total of 2.5 microliters of biotinylated R3VQ / 4G8 mAb at 0,8 mg / ml were injected in the right hippocampus using a Hamilton syringe (1701 RN 10 mL; Hamilton) equipped with a 26G steel needle (7758-02 / 00; Hamilton). The needle was left in place for another 5 minutes after injection. The coordinates of the injection sites were adapted from the Franklin and Paxinos atlas: anterior-posterior axis: 2.2 mm from bregma; medio-lateral axis: 1.3 mm from midline; and dorso-ventral axis: 1.9 mm from dura. Four hours later, brains were collected for histological analysis.

[0254] BBB opening using low-intensity pulsed ultrasound

[0255] Principles of the technique

[0256] The combination of focused ultrasound (US) and microbubbles is a non-invasive technique used to transiently and locally open the BBB.

[0257] Microbubbles, typically composed of a gas core stabilized by a lipid, protein, or polymer shell, are injected intravenously. These microbubbles are small enough (1-10 pm) to circulate freely through the vasculature, including the brain’s capillaries.

[0258] Ultrasound waves are then directed at a specific region of the brain (can be guided by MRI in some protocols requiringveryfocaltargeting). The ultrasound is applied atfrequencies and intensitiesthat are safefortissue but sufficient to interact with circulating microbubbles.When exposed to the ultrasound field, microbubbles within the targeted brain vasculature begin to oscillate (expand and contract) in response to the acoustic pressure. This process is known as stable cavitation. At higher acoustic pressures, microbubbles may undergo inertial cavitation, where they collapse violently, but for BBB opening, parameters are typically set to avoid tissue damage and favor stable cavitation.

[0259] The oscillating microbubbles exert mechanical forces on the endothelial cells lining the brain capillaries. This leads to enhanced permeability of the BBB in the targeted region by 1) temporary widening of tight junctions between endothelial cells, 2) increased transcytosis (vesicle-mediated transport) across the endothelium.

[0260] The BBB opening is localized to the ultrasound-targeted area and is transient, typically lastingfrom minutes to hours. This window allows therapeutic agents circulating in the bloodstream to enter the brain parenchyma at the site of interest. After cessation of ultrasound and clearance of microbubbles, the BBB rapidly restores its integrity, minimizing the risk of prolonged exposure to potentially harmful blood-borne substances.

[0261] Protocol

[0262] In the present study, BBB opening was obtained with low-intensity pulsed ultrasound (LIPU), associated with intravenous injection of microbubbles. LIPU was performed using the LIPU preclinical system (SonoCloud Technology, CarThera, Paris, France), which consists of a 10 mm-diameter ultrasound transducer surrounded by a cylinder filled with previously degassed and deionized water to facilitate acoustic wave transmission and coupled to the head of the mice at a 15 mm distance from the transducer (Fig. 1).

[0263] The parameters were applied as follows: the center frequency was 1 MHz using a pulse length of 25,000 cycles with a pulse-repetition frequency of 1 Hz and an acoustic pressure of 0.2 MPa, as measured in water, for a total duration of 120 s. These parameters were previously optimized and defined as safe in mice. It is subsequently referred to this procedure as the sonication procedure. The complete LIPU sonication procedure was performed as follows. Mice were anesthetized using an intraperitoneal injection of Ketamine (100 mg / kg, solution of 100 mg / mL, Imalgene©, Virbac, France) and xylazine (10 mg / kg, Rompun© 2%, Bayer, La Garenne Colombes, France). The head was shaved and depilated, and xylocaine (tetracaine 0.4%) was applied in each eye for local analgesia. After 2 min, 100 pL of microbubbles (Echography contrast SonoVue©, Bracco Imaging, Evry-Courcouronnes, France) were intravenously injected in the retro-orbital sinus after their reconstitution with physiological serum. A few seconds after the injection, mice were positioned on the ultrasound platform on their backs with their heads maintained in contact with the water and lateralized on their right to target the right hemisphere with the ultrasound beam. LIPU was applied asdescribed above and immediately after the sonication, the mice were then intravenously injected 70 to 90 l (accordingto their weight; 15 mg / kg) of the biotinylated R3VQ monomer in the opposite retro-orbital sinus (non-previously injected). Another group were non-sonicated mice which followed the same protocol except that the ultrasounds were not applied once the mice were placed on the sonication platform. Throughout the whole procedure, except for the time spent for intravenous injection and on the sonication platform, mice were kept in a thermoregulated cage (38 °C) until awakening. Mice were sacrificed 4 hours post-sonication by intraperitoneal injection of pentobarbital (Euthasol©, Cerba Vet, Massy, France, 120 mg / kg). Mice were then intracardially perfused with 4% paraformaldehyde. Brains were extracted and postfixed for 24 h in the same solution.

[0264] Immunofluorescence

[0265] Mouse Brain Tissue Preparation

[0266] Fixed brains were cryoprotected in a dimethylsulfoxide (2%)-glycerol (20%) solution for 24 h. After cryoprotection, brains were cut using a sliding freezing microtome into 40 pm-thick free-floating coronal sections that were stored at -20° C in the cryoprotectant. In order to identify the sonicated (right) hemisphere, a tiny hole was made into the non-sonicated (left) hemisphere using a small-diameter needle (27G). Serial sections were collected from the rostral (frontal pole) to the caudal (brainstem, cerebellum) parts of each brain.

[0267] Fluorescent (IF) immunohistochemistry

[0268] Immunofluorescence was performed to i) detect directly R3VQ-AF488 thanks to its intrinsic fluorescence (Figure 2), ii) to detect biotinylated R3VQ and biotinylated mAb 4G8 injected intracerebrally (Figure 7), as well as biotinylated R3VQ injected intravenously after US-BBB opening (Figure 9) revealed by means of a streptavidin-dylight 680 conjugate (Invitrogen, 1 :250, Catalog # 21848). Co-staining of mouse serum IgGs infiltrating brain tissue after US-BBB opening (Figure 10) was performed with a Goat anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 555 (Invitrogen, 1 :500, Catalog # A-21424). For all experiments, free-floating sections were first incubated for an hour in a PBS triton solution (0.25%) supplemented with bovine serum albumin (4%), to minimize non-specific binding.

[0269] Detection of R3VO injected IV w / wo ultrasound BBB opening

[0270] APPxPS1-Ki mice (n=3) were iv injected at 15 mg / kg biotinylated R3VQ monomer in the orbital sinus with unilateral sonication using low-intensity pulsed ultrasound coupled to iv injected microbubbles or without unilateral sonication and iv injection of microbubbles. Brain sections were then incubated overnight at 4°C in a primary solution of an in-house anti-R3VQ rabbit polyclonal antibodies. The next day, all slices were incubated for an hour and a half at room temperature with a Donkey anti-Rabbit Alexa Fluor™ 555(Invitrogen, 1:500, Catalog # A-31572). Free-floating slices were then mounted on SuperFrost slides and finally coversliped with Prolong™ Gold Antifade Mountant (Invitrogen™, Catalog# P10144). The slides were then imaged using a Nanozoomer scanner (Hamamatsu Photonics, Massy, France) at a 40* magnification.

[0271] Morphological analysis

[0272] The Cavalieri quantification method was used to evaluate the diffusion volume of both R3VQ and 4G8 antibodies injected intracerebrally, as well as R3VQ injected intravenously and plasmatic IgG after sonication. This method allows a volume estimation from serial sections. Images of the coronal brain sections were analyzed using the Ndp.view2 Plus software. Once the brain sections were scanned, the diffusion perimeters of the antibodies were manually outlined, and the surface areas of the defined regions were measured on each section. The diffusion volume was then calculated by applying the Cavalieri principle, which involves multiplying the sum of the surface areas of the diffusion regions by the distance between sections, with a correction factor accounting for the thickness of the sections (Equation 1).

[0273] (n \

[0274] j—(tyyMAx

[0275]

[0276] i-1 /

[0277] Where Vcis the volume to be calculated, d is the distance between sections, n is the number of sections, y, is the diffusion area on the section, t is the section thickness and yMAx is the maximum value of y observed across all sampled sections.

[0278] Results

[0279] Example 1 - R3VQ recognizes A intra- and extracellular pools

[0280] To determine whether R3VQ can recognize both intracellular and extracellular forms of amyloid-p (A3), it was performed immunohistochemistry on brain sections from APPxPSI -Ki mice, a model known to develop both intracellular Ap accumulation and extracellular amyloid plaques.

[0281] As shown in Figure 2, R3VQ produced a specific signal corresponding to A pathology in the APP / PS1 KI brain. In the CA1 region of the hippocampus, it was observed clear intracellular immunoreactivity, consistent with the known distribution of early stage intraneuronal Ap deposits. In addition, strong extracellular labeling was detected in amyloid plaques, further supporting the capacity of R3VQ to bind aggregated forms of Ap.

[0282] Importantly, no staining was observed in wild-type (WT) control brain sections (data not shown), confirming the specificity of R3VQ for pathological Ap species. Together, these results demonstrate that R3VQeffectively recognizes both intracellular and extracellular forms of Ap in situ, including aggregated deposits, and that its binding is specific to brains with Ap pathology.

[0283] Example 2 - Detection of fibrillar and non-fibrillar AB pools (ELISA) by different R3VQ variants To evaluate the binding efficiency of the different formats of the anti-Ap VHH R3VQ, it was performed ELISA assays using two distinct conformations of the Ap 1-42 peptide: non-fibrillar oligomers HFIP treated Ap 1-42, and standard aggregated Ap 1-42. The R3VQ variants (monomer, dimer) were tested at various concentrations on plates coated with either antigen.

[0284] As shown in Figure 3 (coated fibrillized Api-42) and Figure 4 (coated non fibrillized Api-42 HFIP), for both R3VQ formats we observed a concentration-dependent increase in signal for both antigen types. It was also observed no signal in the negative control incubated without any R3VQ but with the secondary antibodies. All these results indicate effective binding to Ap regardless of its aggregation state. Notably, at equivalent concentrations, R3VQ dimer format displayed higher signal than the monomeric format. These findings suggest that R3VQ-dimer has a higher apparent affinity for Ap 1-42 than the monomer.

[0285] Together, these results demonstrate that all tested R3VQ formats are capable of binding both fibrillar and non-fibrillar Ap, with comparable affinity. However, the differences observed in signal intensity between R3VQ formats may also be partially influenced by detection-related biases, such as epitope accessibility or differences in secondary antibody recognition.

[0286] Example 3 - R3VQ inhibits AB aggregation in vitro

[0287] To investigate the effect of the R3VQ VHH variants on the aggregation kinetics of Ap 1-42, it was performed real-time Thioflavin T (ThT) fluorescence assays under two experimental conditions (Fig. 5 and Fig. 6). As expected, incubation of Ap 1-42 alone resulted in a characteristic aggregation profile, with a rapid increase in ThT fluorescence followed by a plateau phase, consistent with the formation and saturation of p-sheet-rich amyloid fibrils. In contrast, Ap 1-42 HFIP treated exhibited only a minimal increase in fluorescence over time with final signal intensities approximately 30-fold lower than those observed with standard Ap 1-42 (Fig.5). These results confirm that HFIP-treated Ap remains predominantly non-fibrillar over the course of the assay, and that ThT fluorescence provides a reliable readout of Ap fibrillization.

[0288] This assay was subsequently used to evaluate the influence of R3VQ on Ap 1 -42 aggregation (Fig. 6). Ap 1 -42 was incubated in the presence of 0.25 molar equivalents of either R3VQ monomer or R3VQ dimer. In both cases, ThT fluorescence was drastically reduced relative to the Ap control, with plateau levels reaching values 20-25 times lower. Strikingly, fluorescence levels, after R3VQ incubation, were similar to those observed with HFIP-treated Ap, suggesting an inhibition of fibril formation. Also, in presence of a non-specific VHH, no inhibition of fibrilLization was observed and the same level of aggregation was obtained as in the A£ control condition (with no VHHs).

[0289] A slightly lower fluorescence signal was observed in the presence of the R3VQ dimer compared to the monomeric variant, indicating a greater inhibitory effect on A£ aggregation. These findings suggest that both R3VQ variants interfere with fibril formation, likely by binding A£ oligomers and preventing their conversion into fibrillar assemblies. The mechanism of inhibition may involve steric hindrance, whereby the antibody formats engage A(3 assemblies and block the conformational transitions or intermolecular interactions necessary for fibril elongation.

[0290] Together, these results demonstrate that R3VQ monomer and dimer effectively suppress A£ 1-42 aggregation, likely through specific, high-affinity interactions with oligomeric A£ species that impede fibril maturation.

[0291] Example 4 - R3VQ has an exquisite potential to diffuse in brain parenchyma

[0292] To evaluate the diffusion potential of R3VQ in the brain parenchyma in vivo, it was stereotactically injected the biotinylated VHH (monomer or dimer) in the dorsal hippocampus of 5-month-old APPxPS1-Ki mice (harboring a dense brain amyloidosis) and it was compared to the diffusion capacity of biotinylated mAb 4G8, a standard anti-AB IgG (BIOLEGEND, Pietersbergweg, 1105 BM AMSTERDAM, PAYS-BAS), 4-hour post-injection.

[0293] At 4-hour post-injection, a specific signal can be observed around the injection site (Fig. 7), with a progressive decrease in signal intensity as the distance from this point increases. This indicates that the antibodies injected intracerebrally diffused through the brain parenchyma in all directions from the injection site.

[0294] For R3VQ, larger diffusion was observed both along the rostro-caudalaxis and in volume, in comparison to 4G8, which shows a much more restricted diffusion signal around the injection point (Figure 7 and 8). No differences were observed in terms of diffusion between monomeric and dimeric R3VQ (Figure 8).

[0295] It was also observed that the signal was more present in sections from the most caudal regions of the mouse brains, suggesting a preferential diffusion of antibodies in this part of the brain. This gradient may be due to a diffusion following interstitial fluid movement ("bulk flow"), which in the telencephalon may be preferentially oriented in the rostro-caudal direction.

[0296] In mice injected with R3VQ, double labeling with 4G8 reveals an overlapping signal, confirming that the injected R3VQ successfully diffused into the brain parenchyma and specifically bound to amyloid plaques (data not shown). A R3VQ signal was also observed inside cells, indicating that R3VQ is capable to crosscell membranes in vivo to potentially reach the intracellular AB pool. No intracellular labeling was observed for injected 4G8 which is compatible with the low capacity of IgGs to cross biological membranes.

[0297] Example 5 - R3VQ CNS penetration and diffusion after BBB opening

[0298] To assess the potential of R3VQ to penetrate and diffuse within the brain parenchyma following iv injection combined to an ultrasound-induced BBB opening, it was injected biotinylated R3VQ monomer by iv at 15 mg / kgin 5-month-old APPxPS1-Ki mice w / wo unilateral sonication and looked at the diffusion of the VHH 4 hours post-injection (Fig. 9 and 10).

[0299] First, it was confirmed that the transient opening of the blood-brain barrier (BBB) had indeed occurred, as evidenced by the infiltration of mouse plasmatic IgG into the brain parenchyma which was revealed through immunofluorescent staining. In fact, it was observed a local increase in IgG labeling in the right hemisphere of mice that underwent the sonication procedure, whereas no increase in signal was detected in mice that received microbubbles without ultrasound exposure (data not shown).

[0300] It was then looked at the diffusion of R3VQ administered intravenously w / wo combination with the BBB opening procedure.

[0301] R3VQ was detected in brain tissue from mice exposed to ultrasound (Fig. 9A), targeting extracellular amyloid deposits, and the areas of the parenchyma where this signal was observed partially overlapped with those showing IgG infiltration and BBB opening in the right hemisphere. An overlap between the signal of the injected R3VQ and a control 4G8 IF signal (illustrating A deposits) confirms that even when administered intravenously, R3VQ retains its specificity for detecting AB peptide accumulations (data not shown).

[0302] Additionally, it was observed an intracellular signal in some cells (data not shown), particularly in the cortex, confirming again the ability of R3VQ to cross cellular membranes in vivo. We also observed that signal from the injected R3VQ was visible in the hemisphere not exposed to pulsed ultrasound, in areas where no IgG infiltration was detected. This confirms the higher capacity of R3VQ (as compared to IgGs) to diffuse in brain parenchyma (Fig. 9A).

[0303] Finally, no significant R3VQ signal was observed in mice that were not exposed to pulsed ultrasound (Fig.

[0304] 9B), clearly demonstratingthe benefit of BBB openingto facilitate the passage of VHHs at the used 15 mg / Kg dosage.

[0305] A quantitative analysis was performed for R3VQ and plasmatic IgG in frontal serial sections of APPxPS1-Ki mice. The diffusion volume of R3VQ is about 4-5 times more important than the diffusion volume of IgG (Fig.

[0306] 10).Overall, these results suggest that intravenously injected R3VQ was able to cross the BBB in regions where pulsed ultrasound induced its opening, and subsequently diffused throughout the brain parenchyma, including into the non-sonicated hemisphere, to reach its targets.

[0307] REFERENCES

[0308] Guo-fang Chen, Ting-hai Xu, Yan Yan, Yu-ren Zhou, Yi Jiang, Karsten Melcher & H Eric Xu. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacologica Sinica volume 38, pagesl 205-1235 (2017)

[0309] Haass C, Schlossmacher MG, Hung AY, Vigopelfrey C, Mellon A, Ostaszewski BL, et al. Amyloid betapeptide is produced by cultured-cells during normal metabolism. Nature 1992; 359: 322-5.

[0310] Haass C, Selkoe DJ. Cellular processing of beta-amyloid precursor protein and the genesis of amyloid betapeptide. Cell 1993; 75: 1039-42.

[0311] GlennerGG, WongCW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein (reprinted from Biochemical and Biophysical Research Communications, Vol 120, Pg 885-890, 1984). Biochem Biophys Res Commun 2012; 425: 534-9.

[0312] Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 2016; 8: 595-608.

[0313] Tengfei Li, Matthias Vandesquille, Fani Koukouli, Clemence Dudeffant, Ihsen Youssef, et al.. Camelid single-domain antibodies: A versatile tool for in vivo imaging of extracellular and intracellular brain targets. Journal of Controlled Release, 2016, 243, pp.1 - 10.

[0314] C. Casas, N. Sergeant, J.M. Itier, V. Blanchard, O. Wirths, N. van der Kolk, V. Vingtdeux, E. van de Steeg, G. Ret, T. Canton, H. Drobecq, A. Clark, B. Bonici, A. Delacourte, J. Benavides, C. Schmitz, G. Tremp, T.A. Bayer, P. Benoit, L. Pradier, Massive CA1 / 2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model, Am. J. Pathol., 165 (4) (2004), pp. 1289-1300

Claims

CLAIMS1. An isolated anti-Ap multimeric single domain antibody comprising two anti-Ap single domain antibodies linked together via a linker,wherein each of the two anti-Ap single domain antibodies comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17, preferably SEQ ID NO: 15.

2. The isolated anti-Ap multimeric single domain antibody according to claim 1, wherein the anti-Ap multimeric single domain antibody comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27 and SEQ ID NO: 28, more preferably the amino acid SEQ ID NO: 25.

3. An anti-Ap single domain antibody or an anti-Ap multimeric single domain antibody comprising two copies of said anti-Ap single domain antibody or a pharmaceutical composition comprising thereof for use in a in vivo method for inhibiting the aggregation of amyloid p, wherein said anti-Ap single domain antibody comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17, preferably SEQ ID NO: 15.

4. An anti-Ap single domain antibody or an anti-Ap multimeric single domain antibody comprising two copies of said anti-Ap single domain antibody or a pharmaceutical composition comprising thereof for use in a method for treatment of a disease associated with the aggregation of Ap, wherein said single domain antibodies comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17.

5. The anti-Ap single domain antibody or the anti-Ap multimeric single domain antibody or the pharmaceutical composition comprising thereof according to claim 4 for use in a method for treatment according to claim 4, wherein the disease associated with the aggregation of Ap is selected from the group consisting of Alzheimer’s disease, Down's syndrome and cerebral amyloid angiopathy.

6. The anti-Ap single domain antibody or the anti-Ap multimeric single domain antibody or the pharmaceutical composition comprising thereof according to any one of claims 3 to 5 for use in a method for inhibiting according to claim 3 or in a method for treatment according to claim 4 or 5, wherein the anti- 35Ap single domain antibody or the anti-Ap multimeric single domain antibody is not linked, directly or indirectly, covalently or non-covalently to another molecule.

7. The anti-Ap single domain antibody or the anti-Ap multimeric single domain antibody or the pharmaceutical composition comprising thereof according to any one of claims 3 to 6 for use in a method for inhibiting according to any one of claims 3 and 6 or in a method for treatment according to any one of claims 4 to 6, wherein the anti-Ap single domain antibody or the anti-Ap multimeric single domain antibody is administered at a dose around 10 mg / kg, 20 mg / kg or up to 50 mg / kg.

8. The anti-Ap single domain antibody or the anti-Ap multimeric single domain antibody or the pharmaceutical composition comprising thereof according to any one of claims 3 to 7 for use in a method for inhibiting according to any one of claims 3 and 6 to 7 or in a method for treatment according to any one of claims 4 to 7, wherein the method comprises a step of applying ultrasound to a region of the brain of the subject.

9. The anti-Ap single domain antibody or the anti-Ap multimeric single domain antibody or the pharmaceutical composition comprising thereof according to any one of claims 3 to 8 for use in a method for inhibiting according to claim 8 or in a method for treatment according claim 8, wherein the region of the brain is the entire brain, hemisphere, forebrain ora region of the brain of the subject known to be associated with Ap aggregates.

10. The anti-Ap single domain antibody or the anti-Ap multimeric single domain antibody or the pharmaceutical composition comprising thereof according to any one of claims 3 to 9 for use in a method for inhibiting according to claim 8 or 9 or in a method for treatment according claim 8 or 9, wherein the acoustic pressure of the ultrasound is between 40 kPa and 3 MPa, preferably 0,2 MPA and / or the waves of the ultrasound is with an emission frequency between 100kHz and 20 MHz, preferably between 100kHz and 3 MHz .

11. The anti-Ap single domain antibody or the anti-Ap multimeric single domain antibody or the pharmaceutical composition comprising thereof according to anyone of claims 3 to 10 for use in a method for inhibiting according to anyone of claims 3 and 6 to 10 or in a method for treatment according to anyone of claims 3 and 6 to 10, wherein the method comprises an additional step of administering microbubbles.3612. The anti-Ap single domain antibody or the anti-Ap multimeric single domain antibody or the pharmaceutical composition comprising thereof according to anyone of claims 3 to 11 for use in a method for inhibiting according to any one of claims 8 to 11 or in a method for treatment according to any one of claims 8 to 11 , wherein the anti-Ap single domain antibody or the anti-Ap multimeric single domain antibody is administered at a dose between 2.5 mg / kg and 10 mg / kg, preferably between 5 mg / kg and 7.5 mg / kg.

13. The anti-Ap single domain antibody or the pharmaceutical composition comprising thereof accordingto anyone of claims 3 to 12 for use in a method for inhibiting accordingto any one of claims 3 and 6 to 12 or in a method for treatment according to any one of claims 4 to 12, wherein the anti-Ap single domain antibody comprises or consists of the amino acid SEQ ID NO: 15.

14. The anti-Ap multimeric single domain antibody orthe pharmaceutical composition comprising thereof according to any one of claims 3 to 12 for use in a method for inhibiting according to any one of claims 3 and 6 to 12 or in a method for treatment according to any one of claims 4 to 12, wherein the anti-Ap multimeric single domain antibody comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27 and SEQ ID NO: 28, preferably the amino acid SEQ ID NO: 25.

15. A method of delivering the anti-Ap single domain antibody or the anti-Ap multimeric single domain antibody as defined in any one of claims 3 to 12, comprising a step of applying ultrasound to a region of the brain of the subject, and optionally a step of administering microbubbles.

16. An isolated nucleic acid sequence that encodes the multimeric single domain antibody according to claim 1 or 2.

17. A vector comprising the nucleic acid sequence accordingto claim 16.

18. A recombinant cell comprising the nucleic acid sequence accordingto claim 16 orthe vector according to claim 17.